GlassScriptPhysician profile
Chintan B Shah
NPI 1871782268
$7,909.67
in general payments reported to CMS, 2019-2025
46 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $1,124 · 2021: $712 · 2022: $693 · 2023: $759 · 2024: $2,205 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191 · Consulting Fee: $1,664 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.74 |
| Consulting Fee | $1,664.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,827.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,664.00 | 2024 | Dupixent |
| Lilly USA, LLC | $493.11 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $469.06 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $439.53 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $249.23 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $235.75 | 2021-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $175.80 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.95 | 2019-2025 | Jascayd |
| Otsuka America Pharmaceutical, INC. | $149.38 | 2022-2024 | Jynarque, Rexulti |
| Ge Healthcare | $127.37 | 2025 | |
| Ucb, INC. | $126.47 | 2019-2020 | |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
| Amgen INC. | $123.35 | 2022-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $113.64 | 2024 | Watchman Flx |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $101.90 | 2019-2021 | |
| Biogen, INC. | $96.67 | 2020-2022 | |
| Corcept Therapeutics | $94.60 | 2025 | Korlym |
| Abbott Laboratories | $94.19 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.55 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $88.34 | 2021-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $78.16 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $69.94 | 2023-2025 | Austedo Xr, Austedo |
| Allergan, INC. | $64.80 | 2020 | |
| Glaxosmithkline, LLC. | $61.06 | 2019-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $54.24 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $51.43 | 2022 | |
| Lundbeck LLC | $51.23 | 2023-2024 | Rexulti, Vyepti |
| Sunovion Pharmaceuticals INC. | $50.48 | 2022 | |
| Acadia Pharmaceuticals INC | $49.84 | 2022 | |
| Sumitomo Pharma America, INC. | $39.25 | 2023-2024 | Gemtesa |
| Genzyme Corporation | $30.68 | 2025 | |
| Mylan Specialty L.P. | $28.10 | 2023 | Yupelri |
| Alkermes, INC. | $24.98 | 2024 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $24.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.89 | 2021 | |
| Daiichi Sankyo INC. | $21.15 | 2025 | Injectafer |
| Evoke Pharma, INC. | $19.63 | 2023 | Gimoti |
| Tactile Systems Technology INC | $19.31 | 2025 | Flexitouch Plus, Nimbl |
| Esperion Therapeutics, INC. | $18.58 | 2021 | |
| Photonicare INC | $18.45 | 2025 | Otosight Middle Ear Scope |
| E.R. Squibb & Sons, L.L.C. | $17.46 | 2023 | Eliquis |
| Astellas Pharma US INC | $16.78 | 2023 | Myrbetriq |
| Avanir Pharmaceuticals, INC. | $14.72 | 2021 | |
| Currax Pharmaceuticals LLC | $13.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chintan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.